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Objective: Isopropylamine NONOate (IPA/NO) is a nitroxyl (HNO) donor at physiologic pH. HNO is a positive
inotrope and vasodilator, but little is known about its effect on neointimal hyperplasia. The aims of this study are to
determine the effect of IPA/NO on endothelial and vascular smooth muscle cells (VSMC) in vitro and to determine if
IPA/NO inhibits neointimal hyperplasia in vivo.
Methods:VSMCwereharvested fromthe abdominal aortas ofmale SpragueDawley rats, andhumanumbilical vein endothelial cells
werepurchased fromATCC. In vitro, cellular proliferationwas assessedby 3H-thymidine incorporation, cellmigrationwas assessed
using the scrape assay, and cell deathwas assessed usingGuava personal cell analysis (PCA). Cell cycle analysis was performed using
propidium iodide staining andflowcytometry analysis. Protein expressionwas assessedusingWesternblot analysis. Phosphorylated
proteinswere assessedusing immunoprecipitation andWesternblot analysis. In vivo, the carotid artery injurymodelwas performed
on male Sprague Dawley rats treated with (n 12) or without (n 6) periadventitial IPA/NO (10 mg). Arteries harvested at 2
weekswere assessed formorphometrics using ImageJ. Inflammationwas assessed using immunohistochemistry. Endothelialization
was assessedbyEvansblue stainingof carotid arteries harvested7days after balloon injury fromrats treatedwith (n6)orwithout
(n 3) periadventitial IPA/NO (10mg).
Results: In vitro, 1000 mol/L IPA/NO inhibited both VSMC (38.7  4.5% inhibition vs control, P  .003) and
endothelial cell proliferation (54.0  2.9% inhibition vs control, P < 0.001) without inducing cell death or inhibiting
migration. In VSMC, this inhibition was associated with an S-phase cell cycle arrest and increased expression of cyclin A,
cyclin D1, and the cyclin-dependent kinase inhibitor p21. No change was noted in the phosphorylation status of cdk2,
cdk4, or cdk6 by IPA/NO. In rodents subjected to the carotid artery balloon injury model, IPA/NO caused significant
reductions in neointimal area (298  20 vs 422  30, P < .001) and medial area (311  14 vs 449  16, P < .001)
compared with injury alone, and reduced macrophage infiltration to 1.7 0.8 from 16.1 3.5 cells per high power field
(P < .001). IPA/NO also prevented re-endothelialization compared with injury alone (55.9  0.5% nonendothelialized
vs 21  4.4%, respectively, P  .001). Lastly, a 50% mortality rate was observed in the IPA/NO-treated groups.
Conclusions: In summary, while IPA/NO modestly inhibited neointimal hyperplasia by inhibiting VSMC proliferation
andmacrophage infiltration, it also inhibited endothelial cell proliferation and induced significant mortality in our animal
model. Since HNO is being investigated as a treatment for congestive heart failure, our results raise some concerns about
the use of IPA/NO in the vasculature and suggest that further studies be conducted on the safety of HNO donors in the
cardiovascular system. (J Vasc Surg 2010;51:1248-59.)
Clinical Relevance: Isopropylamine NONOate (IPA/NO) is a predominately nitroxyl (HNO) releasing compound that is
currently being investigated as a pro-inotropic drug for the cardiovascular system. The effects of IPA/NO on the development of
neointimal hyperplasia havenot been investigated.Here,wedemonstrate that IPA/NOhas amodest beneficial effect onpreventing
the development of neointimal hyperplasia, but IPA/NO also inhibits endothelial cell growth. Given that the latter is less ideal for
a therapy targeted towardpromoting vascular health,we caution its use as an antiproliferative agent in the vasculature.However,we
note that it may be a good antiangiogenic agent for cancer therapeutics.Isopropylamine NONOate (IPA/NO) was originally
synthesized as a diazeniumdiolate by Drago and Karstetter
in 1961.1 However, it was mostly disregarded as a nitric
oxide (NO) donor because it was relatively unstable and its
conversion to NO occurred in relatively low yield.2 Later,
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buffer pH and initial concentration of IPA/NO.3 At phys-
iologic pH, the major pathway of IPA/NO breakdown
yields HNO and isopropanol, and theminor pathway yields
NO and the parent compound, isopropylamine (IPA). The
higher the initial concentration of IPA/NO, and the higher
the pH of the initial solution, the more likely IPA/NO is to
break down to HNO and isopropanol.
Another HNO donor, Angeli’s salt, has been used for
years for in vivo and in vitro studies because it is stable and
decomposes with known kinetics in physiologic buffers.4,5
Like IPA/NO, Angeli’s salt has a short half-life and releases
multiple nitrogen oxides, HNO and nitrite (NO2
), upon
decomposition in solution.4 Unlike Angeli’s salt, IPA/NO
is organic and thus can be further modified with protective
groups to extend the short half-life in physiologic condi-
tions and mitigate any potential side effects from unwanted
breakdown products.
Several recent studies have shown that HNO is a posi-
tive inotrope,6 a vasodilator,7 and subject to redox chem-
istry regulation.8,9 Since the positive inotropic action of
HNO is unaffected by beta-blockers, indeed, it acts syner-
gistically with them,6 and, since the vasodilatory effects of
HNO are not subject to development of tolerance,10 ni-
troxyl donors are being investigated as agents for treatment
of congestive heart failure 11 and replacements for nitro-
glycerin or dobutamine.6,12 These data are the impetus for
the renewed interest in understanding the biochemical and
biologic activity of HNO, especially in its capacity to act
both similar to and opposite of NO in the vasculature.
With the growing amount of evidence suggesting a
therapeutic potential for HNO in the cardiovascular sys-
tem, we sought to determine if the organic HNO donor
IPA/NO would have an effect on the development of
neointimal hyperplasia following arterial injury in the vas-
culature, since this was unknown. Therefore, the aim of this
study was twofold: (1) to determine the effect of IPA/NO
on endothelial and vascular smooth muscle cell (VSMC)
proliferation and death in vitro; and (2) to determine if
IPA/NO inhibits neointimal hyperplasia in vivo. Our hy-
pothesis is that IPA/NOwill inhibit neointimal hyperplasia
following vascular injury.
MATERIALS AND METHODS
Cell culture. VSMC were harvested and cultured
from the abdominal aorta of 10 to 12-week-old male
Sprague-Dawley rats (Harlan, Indianapolis, Ind), and
maintained as previously described.13,14 Human umbilical
vein endothelial cells (HUVEC, line CRL-1730) were
obtained from the American Type Culture Collection
(ATCC, Manassas, Va) and maintained according to
ATCC protocols. Cells were used for in vitro experimenta-
tion between passages 3 and 9.
IPA/NO preparation. IPA/NO was synthesized by
L.K.K. and J.E.S. as previously described.15 Stock solutions
(10 mmol/L) were prepared by dissolving solid IPA/NO
in the appropriate complete culture medium just before
use. The final pH during treatment was 7.8.Griess reaction. To compare the amount of NO re-
leased by IPA/NO and the NO donor diethylenetriamine
NONOate (DETA/NO), a Greiss reaction was conducted.
Briefly, after samples were maintained at 37°C and 5% CO2
for 24 hours, duplicate 100 L aliquots were combined
with an equal volume of the Griess reagents (1% sulfanil-
amide/0.1% naphthylethylenediamine dihydrochloride/
2.5%H3PO4). Nitrite, which is a stable breakdown product
of NO metabolism and serves as a proxy for NO produc-
tion, was measured in the samples by determining their
absorbance at 550 nm in a microplate reader.
Cell proliferation. VSMC or HUVEC plated in 12-
well plates (4  104 cells/well) were growth-arrested for
24 hours in medium without fetal bovine serum (FBS).
Cells were then incubated in complete medium containing
tritiated [3H]-thymidine (5 Ci/mL; PerkinElmer, Welle-
sley, Mass) and IPA/NO (100-1000 mol/L) for 24
hours. [3H]-thymidine incorporated into trichloroacetic-
acid-precipitated DNA was measured with a Wallac
WinSpectral 1414 liquid scintillation counter (Wallac,
Turku, Finland).
Cell death. VSMC or HUVEC were plated and
growth-arrested as above, followed by incubation in com-
plete medium containing IPA/NO (100-1000 mol/L)
for 24 hours. Cells were collected, pelleted, resuspended
in 1 Hank’s balanced salt solution (HBSS) (Invitrogen,
Carlsbad, Calif), diluted fivefold (VSMC) or twofold
(HUVEC) in Guava ViaCount Reagent (Guava Technolo-
gies, Hayward, Calif), and cell death assessed by Guava
personal cell analysis (PCA) as previously described.16-18
Cell migration assay. VSMC and HUVEC plated in
6-well plates (1 105 and 2 105 cells/well, respectively)
were growth-arrested as above.Monolayers were injured by
a single scrape with a 1000 L pipet tip, followed by
treatment with IPA/NO as above, then immediately pho-
tographed, and photographed again 24 hours after treatment.
Blinded counting of nuclei of cells that migrated into the
empty space created by the scrape was performed at both time
points using Adobe Photoshop 8.0 (Adobe Systems Inc, San
Jose, Calif), and quantitation was performed using ImageJ
(National Institutes of Health, Bethesda, Md).
Flow cytometry. VSMC plated in 10-cm plates (9 
105 cells/plate) were growth-arrested as above, then ex-
posed to complete medium containing IPA/NO (100-
1000 mol/L) for 24 hours. Cells were trypsinized, pel-
leted, resuspended in1 phosphate-buffered saline (PBS),
and then fixed with ice-cold 70% ethanol. After ethanol
fixation, cells were resuspended in a propidium iodide (PI)
(Invitrogen, Carlsbad, Calif) staining solution [1 PBS
(pH 7.4), 50 g/mL PI, 204 g/mL RNase A (Sigma, St.
Louis, Mo), 0.1% Triton X-100 (Fischer Biotech, Fair
Lakes, NJ)], incubated for 15 minutes at 37°C, then ana-
lyzed on a Coulter Epic XL flow cytometer (Coulter,
Hialeah, Fla). Data were analyzed using ModFit 3.1 LT
(Verity, Topsham, Me).
Western blot analysis. Whole-cell suspensions of
IPA/NO-treated and untreated VSMC were prepared as
previously described19 and protein concentrations deter-
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the manufacturer’s instructions (Pierce, Rockford, Ill).
Whole-cell suspensions were subjected to acrylamide gel
electrophoresis on 8% to 13% gels, after which proteins
were transferred to a nitrocellulose membrane. Protein
expression was determined using antibodies to p21 (1:
500), p27 (1:1000), cdc2 (1:1000), cyclin-dependent ki-
nase (cdk) 2 (1:1000), cdk4 (1:500), cdk6 (1:1000), cyclin
A (1:1000), and cyclin D1 (1:1000), all from Santa Cruz
Biotechnology, Inc (Santa Cruz, Calif). The antibody to
cyclin B1 (1:250) was from BD Pharmingen (San Jose,
Calif).
Immunoprecipitation. For immunoprecipitations,
IPA/NO-treated and untreated VSMC were lysed using
lysis buffer A (20 mmol/L Tris-HCl [pH 7.5], 150
mmol/L NaCl, 1 mmol/L ethylenediaminetetra-acetic
acid (EDTA), 1 mmol/L ethyleneglycoltetra-acetic acid
(EGTA), 1% (v/v) Triton X-100, 2.5 mmol/L sodium
pyrophosphate, 1 mmol/L -glycerol phosphate, 1
mmol/L sodium orthovanadate, 1 g/mL leupeptin, and
1 mmol/L PMSF) , and 300 g of lysate was incubated
with 1 g of rabbit IgG plus 20 L of protein A/G
sepharose (both from Santa Cruz) for 1 hour at 4°C on a
rotating wheel. The beads were then pelleted by centrifu-
gation for 5 minutes at 1500 rpm and 4°C in an Eppendorf
5417R centrifuge (Westbury, NY), and the supernatant
transferred to a fresh tube, to which was added 20 L of
protein A/G sepharose and 2.5 g of either cdc2, cdk2,
cdk4, or cdk6 antibody. After overnight incubation at 4°C
on a rotating wheel, the beads were pelleted at 2500 rpm
for 15 minutes at 4°C and the supernatants carefully re-
moved. The beads were then subjected to acrylamide gel
electrophoresis, transferred to nitrocellulose membranes,
and protein levels were detected using the antibody con-
centrations listed above. Phosphorylated proteins were de-
tected by phosphothreonine antibody (1:750; Santa Cruz).
Levels of phosphorylated and non-phosphorylated protein
were quantified using ImageJ software.
Animal surgery. All animal procedures were per-
formed in accordance with the Guide for the Care and Use
of Laboratory Animals published by the National Institutes
of Health (NIHPublication 85-23, 1996) and approved by
the Northwestern University Animal Care and Use Com-
mittee. Eleven-week-old male Sprague-Dawley rats weigh-
ing between 350 to 400 g were anesthetized with inhaled
isofluorane (0.5%-3%). Atropine was administered subcu-
taneously (0.1 mg/kg) to decrease airway secretions. After
a midline neck incision, the left common carotid artery
(CCA), external carotid artery (ECA), and the internal
carotid artery (ICA) were dissected and proximal and distal
control obtained with microclips. A transverse arteriotomy
was created on the ECA. A 2F Fogarty catheter (generously
provided by Edward Life Sciences, Irvine, Calif) was in-
serted into the CCA through the ECA, and the CCA
injured by inflating the balloon to 5 atmospheres of pres-
sure for 5 minutes. Following injury, the catheter was
removed, the ECA ligated, and flow restored to the CCA
and ICA, as previously described.16,17,20 After injury andrestoration of flow, 10 mg of IPA/NO powder was applied
evenly to the periadventitial surface of the injured CCA of
rats in the treatment group. The neck incision was closed,
and carotid arteries were harvested at 14 days post-injury.
To obtain the six rats required for statistical significance in
each treatment group, we operated on 12 animals in the
IPA/NO group, due to a 50% mortality rate. Control
groups included no injury and injury alone (n 6/group).
Tissue processing. Carotid arteries were harvested
following in situ perfusion-fixation with cold1 PBS (250
mL) and 2% paraformaldehyde (500 mL). Vessels were
frozen in TissueTek O.C.T. compound (Sakura Finetek
USA, Torrance, Calif) and cut into 5-micron sections
throughout the entire injured segment, as previously de-
scribed.21
Morphometric analysis. Carotid arteries harvested
at 14 days (n  6/group) were examined histologically
for evidence of neointimal hyperplasia using routine
hematoxylin-eosin (H&E) staining. Six equally-spaced sec-
tions from the area of injury were stained from each animal.
Digital images of stained sections were collected with light
microscopy using an Olympus BHT microscope (Melville,
NY) with4 and10 objectives. For morphometric anal-
ysis, intimal area, medial area and arterial circumference
were measured (arbitrary units) using ImageJ software. For
cell density assessment, cell nuclei were counted on three
equally-spaced sections from each animal in each treatment
group by a blinded observer using the 40 objective.
Nuclei were counted in the intima, media, and adventitia
from four high power fields for each section.
Immunohistochemistry. To assess inflammation, ca-
rotid artery sections were also stained for presence of leu-
kocytes and macrophages as follows. After fixation for 5
minutes in cold acetone, sections were permeabilized with
0.3% Trition X-100 for 20 minutes and incubated in 0.3%
hydrogen peroxide in methanol for 15 minutes to block
endogenous peroxidases. After blocking with horse serum
for 30 minutes, primary antibody diluted in 0.5% BSA was
added for 1 hour as follows: anti-CD45 (leukocyte, 1:500),
anti-CD68 (macrophage, 1:500; both from AbD Serotec,
Raleigh, NC). Next, biotinylated secondary antibody di-
luted 1:5000 in 0.5% BSA was added for 1 hour, followed
by addition of streptavidin-bound horseradish peroxidase
for 30 minutes. The stain was developed by incubation in
the chromogen 3,3=-diaminobenzidine tetrahydrochloride
(DAB) for 90 seconds, and a counterstain of hematoxylin
was applied. Coverslips were affixed with gelvatol, and al-
lowed to dry overnight. For each type of staining, six equally-
spaced sections from the area of injury were stained from each
animal. Digital images of stained sections were collected with
light microscopy using an Olympus BHT microscope
(Melville, NY) with4,10 and40 objectives. For inflam-
mation staining, blinded counting of positive cells per high
powered field was performed using ImageJ.
TUNEL staining. To assess the effect of IPA/NO on
cell death in the balloon injury model, rat carotid artery
sections were stained using the DeadEnd Colorimetric
Terminal deoxynucleotidyl transferase dUTP nick end la-
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manufacturer’s instructions. Briefly, sections were washed
in 0.85% NaCl, washed in 1 PBS, and fixed in 4% para-
formaldehyde. After rinsing with 1 PBS, sections were
treated with 20 g/mL proteinase K, and then washed
in 1 PBS and fixed in 4% paraformaldehyde again. After
another wash in1 PBS, sections were covered with equil-
ibration buffer, covered with biotinylated nucleotide mix
and a plastic coverslip, and then incubated for 60minutes at
37°C. The plastic coverslips were removed and the end-
labeling reaction terminated by incubation in 2 sodium
chloride-sodium citrate (SSC) for 15 minutes at room
temperature. After three washes in 1 PBS, the sections
were blocked for endogenous peroxidases and developed
with DAB chromogen as described above. The sections
were coverslipped with gelvatol and sections were digitally
imaged as described above.
Endothelialization. Rat carotid arteries harvested at 7
days post-injury (n  3/group) were examined for endo-
thelialization. To obtain the three rats for each treatment
group, we operated on six animals in the IPA/NO treat-
ment group due to a 50% mortality rate. Thirty minutes
prior to sacrifice, 11-week-old male Sprague-Dawley rats
(Harlan, Indianapolis, Ind) weighing between 395 and
495 g received an intravenous injection of Evans blue dye
(0.5 mL of 0.5%, Sigma, St. Louis, Mo). Following in situ
perfusion with 500 mL of 1 PBS, carotid arteries were
removed and photographed. Areas of denuded endothe-
liumwere identified by blue staining, and the portion of the
injured area stained blue was quantitated using ImageJ.
Statistical analysis. To determine the number of ani-
mals required for each experimental group, a power analysis
was performed. To detect a difference of 20% between the
treatment groups with a power of 0.8, a standard deviation
of 10%, and an alpha of 0.05, an n 6 per treatment group
was required. Results are expressed as mean  standard
error of the mean (SEM). Differences between multiple
groups were analyzed using one-way analysis of variance
(ANOVA) with the Student-Newman-Keuls post hoc test
for all pairwise comparisons (SigmaStat; SPSS, Chicago,
Ill). Statistical significance was assumed when P  .05.
RESULTS
IPA/NO inhibits VSMC and HUVEC prolifera-
tion, but does not cause cell death or inhibit migration
in vitro. To determine the effect of IPA/NOonVSMC and
HUVEC proliferation, 3H-thymidine incorporation was as-
sessed over a range of IPA/NO concentrations (100-1000
mol/L). After 24 hours of treatment, IPA/NO inhibited
proliferation in VSMC in a concentration-dependent man-
ner, with the highest concentration of IPA/NO (1000
mol/L) inducing a 38.7  4.5% inhibition of VSMC
proliferation relative to control (P .003, Fig 1,A), similar
to the NO donor S-nitroso-N-acetylpenicillamine (SNAP,
1000 mol/L). A 54.0  2.9% inhibition of HUVEC
proliferation relative to control was also observed (P 
.001, Fig 2, A). Separate experiments in our laboratory
showed that the NO donor DETA/NO increased endo-thelial cell proliferation at concentrations below 62.5 M,
but inhibited proliferation at higher concentrations, up to
1000 M (data not shown). Proliferation assays were also
performed with the parent compound, isopropylamine
(IPA), and breakdown product, isopropanol, of IPA/NO.
In VSMC, a statistically significant effect on proliferation
was observed with IPA and isopropanol (P  .001, Fig 1,
A), while the effect of IPA and isopropanol in HUVECwas
negligible (Fig 2, A). Of note, Griess reactions revealed
that IPA/NO released significantly less NO than the NO
donor DETA/NO at the same concentration (1000 M).
IPA/NO released 491.8  1.0 M nitrite after 24 hours,
while DETA/NO released 853.4  71.6 M nitrite.
VSMC and HUVEC treated with IPA/NO were as-
sessed for cell death using Guava PCA. No statistically
significant increase in cell death between control and IPA/
NO-treated groups was observed (Figs 1, B and 2, B). IPA,
isopropanol, SNAP (VSMC), andDETA/NO (endothelial
cells, data not shown) also did not induce significant cell
death in either cell type. These results were consistent
across all experimental replicates. Migration assays revealed
that IPA/NO, IPA, or isopropanol had no statistically
significant effect on VSMC or HUVEC migration at 24
hours (Figs 1, C and 2, C).
IPA/NO induces S-phase arrest. To determine the
effect of IPA/NO on cell cycle progression, treated and
untreated VSMC were subjected to flow cytometry analy-
sis. As seen in Fig 3, treatment with IPA/NO for 24 hours
induced a 49% increase in the S-phase population and a
concomitant 20% decrease in the G0/G1 population, com-
pared with control VSMC. These changes were statistically
significant (P  .05 vs control).
IPA/NO affects cell cycle protein expression and
activity. Since IPA/NO inhibited VSMC proliferation in
association with an S-phase cell cycle arrest, Western blot
analysis of IPA/NO-treated VSMC was performed to as-
sess the expression of cell cycle proteins. IPA/NO induced
a marked increase in the expression of the cyclin-dependent
kinase inhibitor (CDKI) p21, relative to untreated cells
(Fig 4, A). Interestingly, IPA/NO lowered the expression of
the CDKI p27 in a concentration-dependent manner, and
caused a large increase in cyclinD1 expression (Fig 4,A). The
cdk4-cyclin D1 complex is known to be inhibited by p27 and
p21, but cdk4 expression did not appear to be affected.
IPA/NO increased the expression of cyclin A, but had no
appreciable effect on cyclinB1, cdc2, cdk2, or cdk6 (Fig 4,A).
With respect to the activity of the cdks, IPA/NOhadno effect
on the level of phosphorylated cdc2, cdk2, cdk4, or cdk6 (Fig
4, B). Taken together, these data suggest that while IPA/NO
affects the expression of the cyclins, as well as the CDKIs p21
and p27, it has a minimal effect on the expression and phos-
phorylation status of the cdks.
IPA/NOmoderates neointimal hyperplasia in vivo.
Since IPA/NO was shown to inhibit VSMC proliferation
in vitro (Fig 1), we sought to determine whether it would
prevent neointimal hyperplasia following balloon arterial
injury in the rat carotid artery in vivo. As can be seen
qualitatively in Fig 5, A, external application of 10 mg of
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rotid artery immediately after balloon injury reduced neo-
intimal area by 29% (Fig 5, B, P  .001), medial area by
31% (P  .001), and had no effect on arterial circumfer-
ence, relative to injury alone. The approximately 30% re-
duction in both intimal and medial area rendered the
traditionally-used metric of intima to media area ratio use-
less, as it was approximately one for both treated and
untreated rats, despite the clearly observed statistically sig-
nificant differences. Cell density analysis revealed that
IPA/NO reduced the number of nuclei in the intima (97.6
8.8 vs 152.8  8.0; P  .001) and media (7.5  0.8 vs
49.3  2.6; P  .001) relative to injury alone, while
increasing the number of nuclei in the adventitia (141.2 
8.1 vs 99.5  8.3; P  .001).
IPA/NO decreases apoptosis in the neointima and
media following balloon injury. Since IPA/NO was
Fig 1. Isopropylamine NONOate (IPA/NO) prevents v
does not cause cell death or affect migration.A, Prolifera
after 24 hours of treatment with IPA/NO.B,VSMC dea
hours of treatment with IPA/NO. C, The effect of IPA
blinded counting of nuclei migrating into the scraped ar
product of IPA/NO, isopropanol, on proliferation, de
effects of the NO donor S-nitroso-N-acetylpenicillamine
mol/L. *P  .005 vs control. †P  .05 vs 1000 m
representative of three separate experiments.shown to inhibit VSMC proliferation without causing celldeath in vitro, and since IPA/NO moderately inhibited
neointimal hyperplasia in vivo, TUNEL staining was per-
formed to assess the effects of IPA/NO on cell death in
vivo. As seen in Fig 6, positive staining for apoptosis is
visible in each layer of the injured artery at 2 weeks, but is
markedly decreased in the neointima and media after ad-
ministration of IPA/NO, with only the adventitia showing
positive staining.
IPA/NO decreases inflammation caused by balloon
injury. To ascertain the effect of IPA/NO on inflamma-
tion in vivo, the presence of leukocytes (CD45) and
macrophages (CD68) in sections of balloon-injured ca-
rotid arteries from IPA/NO-treated and untreated ani-
mals was assessed via immunoperoxidase staining. As
seen in Fig 7, A, no positive staining was observed in
uninjured vessels, while injured vessels showed a marked
increase in both leukocyte and macrophage staining.
ar smooth muscle cell (VSMC) proliferation in vitro, but
f VSMCwas assessed using 3H-thymidine incorporation
s assessed via Guava personal cell analysis (PCA) after 24
(1000 mol/L) on VSMC migration was assessed by
e effects of the parent compound, IPA, and breakdown
d migration were also assessed at 1000 mol/L. The
P) on proliferation and cell death were assessed at 1000







ol/LIPA/NO treatment resulted in a 90% decrease in mac-
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P  .001), but had no significant effect on leukocyte
infiltration.
IPA/NO inhibits re-endothelialization. To further
elucidate the effects of IPA/NO in vivo and confirm the in
vitro HUVEC results, Evans blue staining of treated and
untreated injured carotid arteries was performed. As seen in
Fig 8, A and B, the injured group treated with IPA/NO
had larger areas of positive blue staining in the balloon-
injured area relative to injured rats that received no
IPA/NO (55.9  0.5% vs 21.0  4.4%, P  .001). This
was consistently observed in all IPA/NO-treated rats, and
represents active inhibition of reformation of an intact
endothelial cell layer following arterial injury. Untreated
injured rats were virtually negative for Evans blue staining,
indicating the endothelial cell layer was reformed in these
rats.
DISCUSSION
In this article, we demonstrate that IPA/NO inhibits
Fig 2. Isopropylamine NONOate (IPA/NO) prevents H
affect migration. A, Proliferation of HUVEC was assesse
assessed via Guava personal cell analysis (PCA) after 24
(1000 mol/L) on HUVECmigration was assessed by bl
effects of the parent compound, IPA, and breakdown p
migration were also assessed at 1000 mol/L. *P 
representative of three separate experiments.VSMC and endothelial cell proliferation without inhibitingmigration or inducing cell death. Central to our hypothesis,
periadventitial administration of IPA/NO modestly re-
duced the formation of neointimal hyperplasia and pre-
vented inflammation in an in vivo rodent model of arterial
injury; however, IPA/NO also prevented the reformation
of an intact endothelial cell layer in the injured area, caused
significant mortality in the rat carotid artery balloon injury
model, and depleted the medial layer of cells, raising con-
cerns over the use of HNO donors in vivo.
The main metabolic breakdown product of IPA/NO is
HNO, a highly reactive compound that rapidly and irre-
versibly dimerizes and dehydrates to form nitrous oxide
(N2O).
22 Because this dimerization is so rapid and irrevers-
ible, it is very difficult to measure HNO release in vitro via
a colorimetric assay, like the Griess reaction used to mea-
sure nitrite. While the release profile of IPA/NO has been
described in the chemistry literature,3,23 there have been
relatively few studies of the actions of HNO in the vascu-
lature. However, some of the basic effects of this molecule
have been described. Irvine et al showed that pretreatment
EC proliferation in vitro, but does not cause cell death or
ng 3H-thymidine incorporation. B, HUVEC death was
of treatment with IPA/NO. C, The effect of IPA/NO
counting of nuclei migrating into the scraped area. The
t, isopropanol, of IPA/NO on proliferation, death and





.005of isolated pre-contracted rat aorta with HNO from Angeli’s
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Angeli’s salt;10 however, pretreatment with nitroglycerin
led to induction of tolerance to subsequent nitroglycerin
treatments.10 HNO has also been shown to be a positive
inotrope. Paolocci et al showed that HNO from Angeli’s
salt acted as an inotrope in conscious healthy dogs and dogs
with failing hearts.6,24 The inotropy induced by HNO was
not affected by the -blocker propranolol, and HNO ad-
ministered with dobutamine nearly doubled the inotropic
effect of dobutamine alone.6 Thus, HNO clearly induces
effects in the cardiovascular system, making it a molecule of
interest clinically.
Our work demonstrates that IPA/NO affects VSMC
and endothelial cell proliferation, yet highlights the differ-
ences by which NO and IPA/NO mediate their effects in
the vasculature. NO inhibits VSMC proliferation,14,25,26
and we have shown that IPA/NO also inhibits VSMC
proliferation. NO stimulates endothelial cell prolifera-
tion,26-28 while we have shown that IPA/NO inhibits
endothelial cell proliferation. NO induces VSMC death,27,28
but IPA/NO had no effect on VSMC death. NO and
IPA/NO both induce cell cycle arrest, but where NO is
known to induce G0/G1 cell cycle arrest in VSMC,
19,29
IPA/NO induced S-phase arrest in VSMC. Consistent
Fig 3. Isopropylamine NONOate (IPA/NO) causes S-p
and IPA/NO-treated (1000 mol/L) vascular smooth m
cytometry results after 24 hours of IPA/NO treatment.
representative of three separate experiments.with the inhibition of proliferation, IPA/NO caused in-creased expression of the CDKI p21 in VSMC, similar to
the actions of NO; however, whereas NO increases the
expression of both p21 and p27, IPA/NO decreased p27
expression.14,30 Additionally, IPA/NO increased expres-
sion of both cyclin A and cyclin D1 in VSMC, probably as
a means to overcome cell cycle inhibition. Despite this
increase in cyclin D1 expression, IPA/NO affected neither
the expression of cdk4 or cdk6, nor the level of the active,
phosphorylated versions of these proteins. Lastly, despite
the observed S-phase arrest, IPA/NO had no effect on the
level of phosphorylated cdk2 in VSMC. More work is
required to determine the reasons for the differences be-
tween the effects of NO and IPA/NO. Taken together,
however, these data paint a picture of HNO from IPA/NO
as an important biologic molecule in the vasculature which
can act both similarly to, yet distinct from, NO.
While our study clearly demonstrates that IPA/NO
induces effects in the vasculature that are distinct from
those induced by NO, limitations to this work exist. First,
while we have demonstrated short- and medium-term ef-
fects of IPA/NO in the vasculature of rats,21 these data will
need to be validated in a large animal model. Furthermore,
the durability of this therapy will require examination over
much longer time points. Second, while we evaluated the
cell cycle arrest. A, Flow cytometry analysis of untreated
e cell (VSMC). B, Graphical representation of the flow
.05 vs control. n 3/treatment group. Data shown arehase
uscl
*P effects of the parent compound, IPA, and the breakdown
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study the effects of these compounds in the rat carotid
artery injury model in vivo. Furthermore, while the effects
we observed on VSMC and HUVEC were distinct from
NO, we cannot be certain that NO release did not make a
small contribution to our results. Though characterizations
of IPA/NO have shown it to behave very similarly to
Angeli’s salt, and distinct from NO,23 and IPA/NO is
known to decompose primarily toHNO and isopropanol at
a pH and concentration similar to those used in this work
(L. K. Keefer, unpublished observations), the release pat-
tern of IPA/NO is complex. Therefore, though HNO is
the main molecule released from IPA/NO, the effects of
the other compounds released (ie, NO, isopropanol, IPA)
cannot be discounted. Indeed, isopropanol and isopro-
pylamine are known irritants, and reduced VSMC prolifer-
ation in vitro, so it is possible they are contributing to the
Fig 4. Isopropylamine NONOate (IPA/NO) affects ce
of cdks.A,The expression of cyclins, cdks, and CDKIs we
blot analysis in the presence or absence of IPA/NO fo
experiments. B, IPA/NO-treated and untreated VSM
antibody, then analyzed for expression of phosphorylated
ratio of phosphorylated to non-phosphorylated protein
IPA/NO.effects we observed in vivo.Despite extensive experiments to determine the signal-
ing pathway by which IPA/NO exerted its effects on
VSMC proliferation, we were unable to identify one that
mediated the effects of IPA/NO on VSMC proliferation,
including cGMP and cAMP (data not shown). While it is
clear that IPA/NO acts to lessen the formation of neointi-
mal hyperplasia, the mechanism of this action is not clear.
The results of our immunoperoxidase staining showed that
IPA/NO reduced macrophage infiltration in the neoin-
tima, media, and adventitia of injured vessels. We also
observed fewer nuclei in the media of IPA/NO-treated
arteries, and a paucity of TUNEL positive staining in the
neointima andmedia of IPA/NO-treated arteries. Interest-
ingly, work by other groups has shown that: (1) macro-
phages act as a source of migratory SMC;31 (2) the level of
reactive oxygen species in balloon-injured vessels is in-
creased, leading to a loss of medial cells due to apoptosis;32
le protein expression, but not the phosphorylation state
essed in vascular smoothmuscle cell (VSMC) byWestern
hours. Data shown are representative of three separate
ates were immunoprecipitated (IP) with the indicated
and non-phosphorylated (non-P) cdks. Graphs show the





as detand (3) adventitial fibroblasts convert to myofibroblasts
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Given all these data, we speculate that periadventitial appli-
cation of IPA/NO reduces the formation of neointimal
hyperplasia and repopulation of the media by preventing
Fig 5. IsopropylamineNONOate (IPA/NO) moderate
arteries treated with or without exogenous periadventitia
14 days after injury and stained by H&E. Whole mount
area, medial area and arterial circumference using ImageJ
arbitrary.
Fig 6. Isopropylamine NONOate (IPA/NO) decrease
arteries. Balloon-injured rat carotid arteries treated w
IPA/NO powder (10 mg) and harvested 14 days after i
apoptosis. Arrows indicate positive staining.the migration and differentiation of macrophages and ad-ventitial fibroblasts, as well as by inhibiting VSMC prolif-
eration. This hypothesis is indirectly supported by our cell
density data, which demonstrates a stark lack of nuclei in
the media of IPA/NO-treated arteries, as well as an in-
intimal hyperplasia in vivo.A,Balloon-injured rat carotid
inistration of IPA/NO powder (10 mg) were harvested
close-up sections are shown. B, Quantitation of intimal
are (n 6/group). *P .001 vs injury alone. Units are
ptosis in the neointima and media of balloon-injured
r without exogenous periadventitial administration of





njurycrease in the number of adventitial nuclei, and may also
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neointima of IPA/NO-treated arteries.
Another important limitation to the use of HNO in the
vasculature deserves mention. Though HNO donors seem
promising due to their specificity and chemistry distinct
from that of NO, the question of toxicity remains an
important one. In the course of this study, we operated on
12 rats to obtain the group of six required for statistical
significance. The rate of this mortality, which we believe
was secondary to airway edema, was much higher than that
observed using diazeniumdiolates that donate primarily
Fig 7. Isopropylamine NONOate (IPA/NO) decreases
rat carotid arteries treated with or without exogenous pe
harvested 14 days after injury (n  6/group) were subje
leukocytes (CD45) and macrophages (CD68). Arrows i
CD45 and CD68 staining in untreated and IPA/NO
6/group). *P  .001 vs injury alone.NO, so this effect may be related to the HNO released byIPA/NO. Consistent with this IPA/NO-induced increase
in animal mortality, early studies did show that the HNO
donor Angeli’s salt was cytotoxic.34 Furthermore, it is
known that breakdown products of some of the diazenium-
diolates are potentially toxic amines.35 Thus, toxicity of any
HNO donor must be addressed prior to administration of
these compounds to patients.
Lastly, since the endothelial cell layer produces many
vasoprotective molecules and serves as a natural barrier of
the vascular wall against platelets and leukocytes, the ob-
servation that IPA/NO prevents reformation of the endo-
mmation in balloon-injured arteries. A, Balloon-injured
entitial administration of IPA/NO powder (10 mg) and
to immunoperoxidase staining using antibodies against
te positive staining. B, Blinded quantitation of positive




-treatthelial layer is highly problematic in terms of its use as a
 .00
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effect of IPA/NO delivery in vivo with respect to its anti-
proliferative effects on endothelial cells calls to mind the
effects of the FDA-approved coronary artery drug-eluting
stents, which release sirolimus and paclitaxel. Several
pooled or meta-analysis studies have revealed either similar
mortality or worse mortality of these drug-eluting stents
compared with bare-metal stents.36,37 Thus, it stands to
reason that IPA/NOmay be subject to the same potentially
deleterious effects in the vasculature if used to prevent the
development of neointimal hyperplasia in vivo.
In summary, we found that IPA/NO, an organicHNO
donor, inhibited VSMC and endothelial cell proliferation
in vitro without inhibitingmigration or inducing cell death.
This inhibition of VSMC proliferation was mediated
through S-phase cell cycle arrest. IPA/NO also modestly
inhibited the development of neointimal hyperplasia fol-
lowing arterial injury in vivo and reduced inflammation.
However, IPA/NO prevented reformation of an intact
endothelial cell layer and caused significant mortality in
vivo. Thus, although HNO donors may be useful in treat-
ing a variety of cardiovascular diseases, the concerns raised
by our data, and those of others, must be fully addressed
Fig 8. Isopropylamine NONOate (IPA/NO) prevents
tered Evans blue dye intravenously 7 days post-injury, an
the extent of endothelial regeneration. Blue staining indi
photographs from panel (A) using ImageJ software. *Pbefore these compounds should be used clinically.The authors would like to express their thanks to
Edwards Life Sciences (Irvine,Calif) for generously provid-
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